TIDMCREO
Creo Medical Group PLC
16 August 2023
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Royal Oldham SSD service going from strength to strength
40 cases completed in record time, with patients and waiting
lists experiencing immediate benefits
Creo Medical Group plc (AIM: CREO), the medical device company
focused on the emerging field of minimally invasive surgical
endoscopy, provides an update on the implementation of its
technology within The Royal Oldham Hospital ("Royal Oldham"). On 17
May, Creo announced that Royal Oldham had become the first NHS
hospital to immediately implement CROMA and Speedboat(TM) Inject
across multiple endoscopy rooms, putting in place weekly lists for
multiple SSD (Speedboat Submucosal Dissection) cases.
The hospital has now treated over 40 patients using the new
service, representing the fastest time for any NHS hospital to
reach the landmark, with exceptional results for patients, the
hospital and its staff. Multiple doctors at the hospital have
already progressed through Creo's Pioneer Programme mentoring stage
and are independently treating regular lists of patients presenting
with complex, high-risk lesions in the colon.
Creo has a target base for the Speedboat range of products of
more than 350 NHS hospitals, with each SSD procedure demonstrated
to save the NHS up to GBP10k when compared to traditional surgery,
alongside a typically far shorter hospital stay and significantly
lower risk of complications. There are 23 NHS England healthcare
settings that have now adopted SSD.
Dr Sal Khalid, Consultant Gastroenterologist at the Royal Oldham
Hospital, said: "I'm very pleased with the outcomes the Speedboat
Inject device is facilitating for our patients, allowing our
advanced endoscopists to remove complex high-risk lesions and even
early cancer without the patient requiring invasive surgical
treatment.
"Almost all bowel cancers start as a lesion, and so having the
technology now available to us to cut deeper and more safely
through the layers of the bowel when removing a lesion enables us
to ensure that it's completely removed and reduce the chances of
patients requiring an operation.
"It's already clear that this will have a lasting effect, with
the treatment reducing the chances of recurrence from 15% to 1% and
potentially providing a cure for lesions containing early cancer
without requiring operation.
"Indeed, only three months into the new service we are already
recording a reduction in the waiting lists not only across our
endoscopy suites but, perhaps most importantly, in terms of those
waiting for the surgical treatment of more invasive cancers.
"The best part about the new service is being able to call a
patient a few days later and tell them that they have had a
curative outcome - that the lesion has been removed with the
necessary margins not to have to worry about it anymore. That was
rarely the case before we introduced Speedboat Inject and the
advanced energy.
" The establishment of this service will help us maintain our
status as one of the leading advanced endoscopy services in the
country and help us move towards our goal of prevention, early
detection, and treatment of bowel cancer."
Dr Khalid has now completed over 15 procedures using the
Speedboat Inject device. Out of the first 10 cases, two were
confirmed as cancers and three as showing features of high grade
dysplasia, suggesting lesions very close to turning into a cancer.
All of these lesions were successfully removed completely through
an SSD procedure using Creo's advanced energy device.
What next?
-- SSD will become Royal Oldham's treatment of choice for
high-risk polyps suspected of containing early cancer. Hundreds of
patients every year are expected to benefit from this treatment
option.
-- Royal Oldham plans to expand the service and increase the
number of conditions it can treat using this equipment. This will
involve training endoscopists to perform a wider array of
procedures using CROMA and Speedboat.
-- An expanded service will be supported by a dedicated
multidisciplinary team involving experts from across all the
relevant specialties, ensuring every patient gets the best
treatment based on expert knowledge, with every decision supported
by the most current medical evidence.
-- Royal Oldham will also aim to offer training opportunities to
help teach this advanced technique to a wider pool of doctors,
including the establishment of training posts of Endoscopy Fellows
who will receive dedicated training and experience of decision
making and performing SSD procedures under direct supervision of Dr
Sal Khalid and his team.
Craig Gulliford, CEO of Creo Medical said: "Oldham provides a
phenomenal model for what's possible when a hospital immediately
recognises the potential of the device and implements the right
pathways and resource to maximise its impact.
"To know that there are 40 patients in and around Oldham who
have already benefited from our technology and the excellent
service provided by Dr Khalid and his team is incredibly
gratifying, with the knock-on positive effects on waiting lists and
hospital resources now well established.
"To hear plans for the further expansion of the service is also
excellent news and we look forward to supporting the hospital in
every way we can."
Enquiries:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson (Sales)
Numis Securities Limited (Joint
Broker)
Freddie Barnfield / Duncan Monteith
/ Euan Brown +44 (0)20 7260 1000
Walbrook PR Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502
Phillip Marriage 558 258
+44 (0)7867 984 082
About Creo Medical
Creo Medical is a medical device company focused on the
development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the
development and commercialisation of a suite of electrosurgical
medical devices, each enabled by CROMA, powered by Kamaptive. The
Group has developed the CROMA powered by Kamaptive full-spectrum
adaptive technology to optimise surgical capability and patient
outcomes. Kamaptive is a seamless, intuitive integration of
multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection,
coagulation and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled
surgical solutions. CROMA currently delivers bipolar radiofrequency
("RF") energy for precise localised cutting and focused high
frequency microwave ("MW") energy for controlled coagulation and
ablation via a single accessory port. This technology, combined
with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and
controlled clinical solutions. The Directors believe the Company's
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option for
procedures.
For more information, please refer to the website
www.creomedical.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEALPSFALDEFA
(END) Dow Jones Newswires
August 16, 2023 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024